OTCQB:VVCIF - Post Discussion
Post by
1hot-techwoman on Mar 01, 2023 10:17am
Merger will be good for Vivo going forward with Medipharm !!
As we approach Q2. With several trials either commencing Phase 2 or right around the corner, it should generate some buzz should any of these trials prove effective
Interesting the Keck research into AAD recieved FDA approval. Once word gets out the CBD is in fact a viable alternative treatment for so many ailments, Medipharm will be well positioned to benefit big time.
| Researcher | Indication | Phase | Recent Milestone |
| USC (University of Southern California) Keck School of Medicine | Treatment of Alzheimer's Agitation Disorder | Two | FDA approval of Investigational New Drug (IND) |
| McMaster University | Treatment of post-surgical pain | Two | Clinical trial material (CTM) delivered and enrollment commencing in Q1 2023 |
| University Health Network - Toronto | Improving Pain Disability With The Use Of Oral Cannabinoids | Pilot | CTM Delivered and enrollment clinic in Q1 2023 |
| McMaster University | Insomnia in depressive disorder | Two | CTM Shipment in Q1 2023 |
| Centre for Medical Cannabis Research | PK of single dose THC/CBD in healthy adult controls and kidney disease | One | 1st patient dosed January 2023 |
| University of Manitoba | Chronic Headaches in Adolescents | Two | Health Canada approval Dec 2022. CTM shipment in Q1 2023 |
Be the first to comment on this post